Orlistat vs Ozempic: How do they compare for weight management?
- How orlistat and Ozempic work differently
- How their weight loss outcomes compare
- The important UK licensing distinction between Ozempic and Wegovy
- Who each option is most likely to suit
- Whether the two can be taken together
An important regulatory distinction
Before comparing the two medicines, one point needs clarifying. Ozempic (semaglutide 1 mg) is licensed in the UK for the treatment of type 2 diabetes, not for weight loss. Wegovy (semaglutide 2.4 mg) is the MHRA-licensed version of semaglutide for weight management, approved under NICE TA875 in March 2023.
Warning!
Ozempic should not be sought as a weight-loss treatment in place of Wegovy. Current NHS and professional guidance prioritises Ozempic supply for patients with type 2 diabetes who depend on it. Any prescriber offering Ozempic off-label for weight loss should explain this clearly and justify why the licensed alternative, Wegovy, is not being used instead.
Where semaglutide is used for weight management, Wegovy is the appropriate licensed option. This article uses Ozempic as the commonly searched term but reflects this distinction throughout.
How do they work?
| Orlistat | Ozempic/semaglutide | |
|---|---|---|
| Mechanism | Lipase inhibitor | GLP-1 receptor agonist |
| How it works | Blocks fat absorption in the gut | Reduces appetite via brain signalling; slows gastric emptying |
| Administration | Oral capsule, three times daily with meals | Weekly subcutaneous injection |
| Licensed for weight loss in UK | Yes (NICE TA22) | Ozempic: No (T2D only). Wegovy: Yes (NICE TA875) |
Orlistat works by inhibiting pancreatic lipase, the enzyme responsible for breaking down dietary fat in the gut. Undigested fat passes through the body rather than being absorbed, reducing calorie intake from fat by approximately 30%. It does not affect appetite or hormones. For a full explanation of the mechanism, see our guide to how orlistat works.
Semaglutide (whether as Ozempic or Wegovy) works by mimicking GLP-1, a gut hormone released after eating. It acts on appetite centres in the brain to reduce hunger, slows gastric emptying to increase feelings of fullness, and improves blood sugar regulation. The result is a significant and sustained reduction in overall food intake.
How do the weight loss outcomes compare?
The clinical evidence favours semaglutide significantly over orlistat for weight loss outcomes.
Orlistat, reviewed under NICE TA22, produces average weight loss of approximately 3-5% of body weight over 12 months in clinical trials, compared to placebo. Around 35-54% of patients achieve at least 5% weight loss with orlistat.
Wegovy (semaglutide 2.4 mg), assessed in the STEP 1 trial, produced average weight loss of 14.9% of starting body weight over 68 weeks, with approximately 86% of participants achieving at least 5% weight loss. The STEP UP trial showed average weight loss of 20.7% at the 7.2 mg dose.
The difference in outcomes is substantial and clinically meaningful. Semaglutide is considerably more effective for weight loss than orlistat across all published comparisons.
Side effect comparison
| Side effect | Orlistat | Semaglutide (Wegovy/Ozempic) |
|---|---|---|
| Gastrointestinal effects | Oily or fatty stools, faecal urgency, flatulence | Nausea, vomiting, diarrhoea, constipation |
| Nature of GI effects | Diet-dependent; worse with high-fat meals | Dose-dependent; most pronounced during titration |
| Appetite suppression | No | Yes |
| Injection-site reactions | No | Yes (weekly injection) |
| Serious rare risks | Severe liver injury (rare) | Pancreatitis, gallbladder disease (rare) |
Orlistat's side effects are directly linked to dietary fat intake. Men who follow the recommended low-fat diet experience fewer GI symptoms. Those who eat high-fat meals risk significant and unpredictable GI effects that many patients find difficult to manage socially. For a full overview of orlistat's side effect profile, see our orlistat side effects guide.
Semaglutide's GI side effects are most pronounced in the early weeks and during dose increases, typically improving as the body adjusts to the medication.
Who does each option suit?
Orlistat may be more appropriate if:
- You prefer an oral tablet to a weekly injection
- You have a relatively low BMI (27 or above with a comorbidity, or 30 or above) and want a lower-intensity intervention
- Cost is a primary consideration, as orlistat is available at lower cost and on NHS prescription
- You are not suitable for GLP-1 medicines due to contraindications or personal preference
Wegovy (semaglutide) may be more appropriate if:
- You have a higher starting BMI and are seeking more significant weight loss
- You have type 2 diabetes alongside obesity (Ozempic may be appropriate via the diabetes prescribing pathway)
- You are eligible for NHS specialist weight management services under NICE TA875
- Previous attempts with orlistat have not produced sufficient results
If you are considering injectable GLP-1 treatment and want to compare orlistat against Mounjaro specifically, see our orlistat vs Mounjaro guide.
Cost comparison
Orlistat is available on NHS prescription for eligible patients at the standard 120 mg dose. A lower-strength version (Alli 60 mg) is also available to buy over the counter from UK pharmacies without a prescription. Private prescription costs are modest compared to injectable GLP-1 medicines.
Wegovy carries a significantly higher private prescription cost, typically £169 to £289 per month at the standard 2.4 mg maintenance dose. NHS access is available through specialist services under NICE TA875 for eligible patients, at the standard prescription charge.
For current pricing, visit the DoktorABC website for up-to-date information across available doses and pack sizes.
Can you take orlistat and Ozempic together?
There is no established evidence base for combining orlistat and semaglutide, and this combination is not standard clinical practice. Both affect gastrointestinal function through different mechanisms, and combining them may increase GI side effect burden. Any consideration of combination use should involve a clinician assessment and not be undertaken independently.
Good to know
If you are already taking one of these medicines and are not achieving sufficient weight loss, speak to your prescriber about whether adjusting your current treatment or switching to an alternative is more appropriate than adding a second medicine.
Final thoughts
Orlistat and semaglutide are both legitimate tools for weight management, but they operate at very different levels of efficacy. For patients seeking modest support alongside dietary changes, orlistat remains a practical and accessible option. For those requiring more significant weight loss, Wegovy (the licensed weight-management form of semaglutide) has a substantially stronger evidence base. The right choice depends on your individual health profile, eligibility, and treatment goals, and should always be guided by a clinical assessment.
DoktorABC connects UK patients with licensed prescribers who can assess suitability for weight management treatments and provide ongoing clinical guidance.
FAQ
Is Ozempic the same as Wegovy?
Both contain semaglutide, but they are different products with different licensed indications. Ozempic is licensed for type 2 diabetes in the UK; Wegovy is licensed for weight management. For weight loss, Wegovy is the appropriate licensed option.
Is orlistat or Ozempic better for weight loss?
Semaglutide (as Wegovy) produces substantially greater average weight loss than orlistat in clinical trials: approximately 14.9% versus 3-5% of starting body weight. However, eligibility, cost, and individual health factors all influence which is appropriate for a given patient.
Can I get orlistat or Wegovy on the NHS?
Orlistat is available on NHS prescription for eligible patients. Wegovy is available through specialist NHS weight management services under NICE TA875. Speak to your GP about eligibility for either.
Does orlistat or Ozempic cause more side effects?
Both have gastrointestinal side effect profiles, but the nature differs. Orlistat causes oily stools and faecal urgency, which are diet-dependent. Semaglutide causes nausea, vomiting, and diarrhoea, which are most pronounced during titration and typically improve over time.
Can you use orlistat and Ozempic at the same time?
This is not standard clinical practice and should only be considered under medical supervision. Do not combine the two without a clinical assessment.
The DoktorABC medical advisory board
Dr. Roland Ruiken
Medical advisor, Norway
Dr. Viktor Simunovic
Medical advisor, Croatia